IP Library Granted Patent US 9,649,171
Granted Patent B2
US 9,649,171 · App. 14/962,348 · Granted May 16, 2017

Systems and methods for treatment planning based on plaque progression and regression curves

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,649,171
App. No.
14/962,348
Granted
May 16, 2017
Kind
B2
Abstract

Systems and methods are disclosed for evaluating a patient with vascular disease. One method includes receiving patient-specific data regarding a geometry of the patient's vasculature; creating an anatomic model representing at least a portion of a location of disease in the patient's vasculature based on the received patient-specific data; identifying one or more changes in geometry of the anatomic model based on a modeled progression or regression of disease at the location; calculating one or more values of a blood flow characteristic within the patient's vasculature using a computational model based on the identified one or more changes in geometry of the anatomic model; and generating an electronic graphical display of a relationship between the one or more values of the calculated blood flow characteristic and the identified one or more changes in geometry of the anatomic model.

Claims (65)

1. A computer-implemented method of evaluating a patient with vascular disease, the method comprising:

receiving or determining patient-specific data representing at least a portion of a location of disease in the patient's vasculature;

receiving or determining, from the patient-specific data, values of one or more plaque remodeling characteristics at the location of disease, the one or more plaque remodeling characteristics including at least one of: plaque composition, plaque location, plaque vulnerability, hemodynamic forces, intramural stress, and/or plaque inflammatory status;

calculating, based on the received or determined values of the one or more plaque remodeling characteristics, a propensity of the disease in the patient's vasculature to progress or regress;

generating, using the calculated propensity, an anatomic model of the location of disease at a first point of time;

identifying, based on the calculated propensity, a progression or regression of the disease in the patient's vasculature by modeling the progression or the regression of the disease using the generated anatomic model;

identifying a second point of time different from the first point of time, the second point of time being associated with the progression or regression of the disease in the patient's vasculature; and

generating a display including the identified progression or regression of the disease at the location of disease at the second point of time or generating a display including recommending assessment of the progression or regression of disease at the location of disease at the second point of time.

2. The computer-implemented method of claim 1 , wherein the second point of time includes a time at which the disease becomes functionally significant or wherein the second point of time includes a time at which the disease ceases to be functionally significant.

3. The computer-implemented method of claim 1 , further comprising:

determining a disease type associated with the disease associated with the calculated propensity; and

determining one or more disease predictions or one or more treatment plans based on the determined disease type.

4. The computer-implemented method of claim 1 , further comprising:

determining a patient medical or physical condition; and

determining or updating the second point of time based on the determined patient medical or physical condition.

5. The computer-implemented method of claim 1 , further comprising:

determining a rate of progression or regression of the disease; and

determining the second point of time based on the rate of progression or regression of the disease.

6. The computer-implemented method of claim 5 , further comprising:

determining a rate of progression or regression of the disease, wherein the rate of progression or regression of the disease is based on the location of disease.

7. The computer-implemented method of claim 1 , further comprising:

determining a time interval, wherein the second point of time is temporally spaced from the first point of time at the determined time interval; and

updating the display or the recommendation at the determined time interval.

8. The computer-implemented method of claim 1 , wherein the disease includes the presence of plaque.

9. A system for evaluating a patient with vascular disease, the system comprising:

a data storage device storing instructions for evaluating a patient with vascular disease; and

a processor configured to execute the instructions to perform a method including:

receiving or determining patient-specific data representing at least a portion of a location of disease in the patient's vasculature;

receiving or determining, from the patient-specific data, values of one or more plaque remodeling characteristics at the location of disease, the one or more plaque remodeling characteristics including at least one of: plaque composition, plaque location, plaque vulnerability, hemodynamic forces, intramural stress, and/or plaque inflammatory status;

calculating, based on the received or determined values of the one or more plaque remodeling characteristics, a propensity of the disease in the patient's vasculature to progress or regress;

generating, using the calculated propensity, an anatomic model of the location of disease at a first point of time;

identifying, based on the calculated propensity, a progression or regression of the disease in the patient's vasculature by modeling the progression or the regression of the disease using the generated anatomic model;

identifying a second point of time different from the first point of time, the second point of time being associated with the progression or regression of the disease in the patient's vasculature; and

generating a display including the identified progression or regression of the disease at the location of disease at the second point of time or generating a display including recommending assessment of the progression or regression of disease at the location of disease at the second point of time.

10. The system of claim 9 , wherein the second point of time includes a time at which the disease becomes functionally significant or wherein the second point of time includes a time at which the disease ceases to be functionally significant.

11. The system of claim 9 , wherein the system is further configured for:

determining a disease type associated with the disease associated with the calculated propensity; and

determining one or more disease predictions or one or more treatment plans based on the determined disease type.

12. The system of claim 9 , wherein the system is further configured for:

determining a patient medical or physical condition; and

determining or updating the second point of time based on the determined patient medical or physical condition.

13. The system of claim 9 , wherein the system is further configured for:

determining a rate of progression or regression of the disease; and

determining the second point of time based on the rate of progression or regression of the disease.

14. The system of claim 13 , wherein the system is further configured for:

determining a rate of progression or regression of the disease, wherein the rate of progression or regression of the disease is based on the location of disease.

15. The system of claim 9 , wherein the system is further configured for:

determining a time interval, wherein the second point of time is temporally spaced from the first point of time at the determined time interval; and

updating the display or the recommendation at the determined time interval.

16. The system of claim 9 , wherein the disease includes the presence of plaque.

17. A non-transitory computer readable medium for use on a computer system containing computer-executable programming instructions for performing a method of evaluating a patient with vascular disease, the method comprising:

receiving or determining patient-specific data representing at least a portion of a location of disease in the patient's vasculature;

receiving or determining, from the patient-specific data, values of one or more plaque remodeling characteristics at the location of disease, the one or more plaque remodeling characteristics including at least one of: plaque composition, plaque location, plaque vulnerability, hemodynamic forces, intramural stress, and/or plaque inflammatory status;

calculating, based on the received or determined values of the one or more plaque remodeling characteristics, a propensity of the disease in the patient's vasculature to progress or regress;

generating, using the calculated propensity, an anatomic model of the location of disease at a first point of time;

identifying, based on the calculated propensity, a progression or regression of the disease in the patient's vasculature by modeling the progression or the regression of the disease using the generated anatomic model;

identifying a second point of time different from the first point of time, the second point of time being associated with the progression or regression of the disease in the patient's vasculature; and

generating a display including the identified progression or regression of the disease at the location of disease at the second point of time or generating a display including recommending assessment of the progression or regression of disease at the location of disease at the second point of time.

18. The non-transitory computer readable medium of claim 17 , wherein the second point of time includes a time at which the disease becomes functionally significant or wherein the second point of time includes a time at which the disease ceases to be functionally significant.

19. The non-transitory computer readable medium of claim 17 , the method further comprising:

determining a disease type associated with the disease associated with the calculated propensity; and

determining one or more disease predictions or one or more treatment plans based on the determined disease type.

20. The non-transitory computer readable medium of claim 17 , the method further comprising:

determining a patient medical or physical condition; and

determining or updating the second point of time based on the determined patient medical or physical condition.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Sep 11, 2025
From: HAYFIN SERVICES LLP
To: HEARTFLOW, INC.
Reel/Frame 072876/0775 →
RELEASE OF SECURITY INTEREST Recorded Jun 21, 2024
From: HAYFIN SERVICES LLP
To: HEARTFLOW, INC.
Reel/Frame 067801/0032 →
SECURITY INTEREST Recorded Jun 18, 2024
From: HEARTFLOW, INC.
To: HAYFIN SERVICES LLP
Reel/Frame 067775/0966 →
SECURITY INTEREST Recorded Jan 20, 2021
From: HEARTFLOW, INC.
To: HAYFIN SERVICES LLP
Reel/Frame 055037/0890 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 25, 2017
From: SANKARAN, SETHURAMAN; TAYLOR, CHARLES A.; CHOI, GILWOO; SCHAAP, MICHIEL; ZARINS, CHRISTOPHER K.; GRADY, LEO J.
To: HEARTFLOW, INC.
Reel/Frame 043682/0501 →